Summary of selected clinical and molecular characteristics of the samples in BL cohort
| Variable . | Level . | Adult (n = l00) . | Pediatric (n = 181) . | Total (n = 281) . |
|---|---|---|---|---|
| EBV status | EBV-negative | 67 (67) | 66 (36) | 133 (47) |
| EBV-positive | 33 (33) | 115 (64) | 148 (53) | |
| Sex | Female | 29 (29) | 55 (30) | 84 (30) |
| Male | 70 (70) | 123 (68) | 193 (68) | |
| Unknown | 1 (1) | 3 (2) | 4 (1) | |
| Clinical variant | Endemic | 1 (1) | 118 (65) | 119 (42) |
| Sporadic | 99 (99) | 63 (35) | 162 (58) | |
| BLIPI | 0 | 11 (11) | 34 (19) | 45 (16) |
| 1 | 25 (25) | 24 (13) | 49 (17) | |
| 2 | 19 (19) | 17 (9) | 36 (13) | |
| 3 | 6 (6) | 2 (1) | 8 (3) | |
| 4 | 3 (3) | 0 (0) | 3 (1) | |
| Unknown | 36 (36) | 104 (57) | 140 (50) | |
| HIV status | HIV-negative | 59 (59) | 146 (81) | 205 (73) |
| HIV-positive | 24 (24) | 6 (3) | 30 (11) | |
| Unknown | 17 (17) | 29 (16) | 46 (16) | |
| First-line regimen | CODOX/IVAC±R | 34 (34) | 3 (2) | 37 (13) |
| COM | 0 (0) | 39 (22) | 39 (14) | |
| COP | 0 (0) | 16 (9) | 16 (6) | |
| DA-EPOCH±R | 6 (6) | 9 (5) | 15 (5) | |
| No treatment | 0 (0) | 5 (3) | 5 (2) | |
| Other | 8 (8) | 6 (3) | 14 (5) | |
| Unknown | 52 (52) | 103 (57) | 155 (55) | |
| PFS | Median, y | 2.87 | 0.85 | 1.64 |
| No. (%) | 88 (88) | 165 (91) | 253 (90) | |
| OS | Median, y | 2.89 | 1.02 | 1.82 |
| No. (%) | 88 (88) | 165 (91) | 253 (90) |
| Variable . | Level . | Adult (n = l00) . | Pediatric (n = 181) . | Total (n = 281) . |
|---|---|---|---|---|
| EBV status | EBV-negative | 67 (67) | 66 (36) | 133 (47) |
| EBV-positive | 33 (33) | 115 (64) | 148 (53) | |
| Sex | Female | 29 (29) | 55 (30) | 84 (30) |
| Male | 70 (70) | 123 (68) | 193 (68) | |
| Unknown | 1 (1) | 3 (2) | 4 (1) | |
| Clinical variant | Endemic | 1 (1) | 118 (65) | 119 (42) |
| Sporadic | 99 (99) | 63 (35) | 162 (58) | |
| BLIPI | 0 | 11 (11) | 34 (19) | 45 (16) |
| 1 | 25 (25) | 24 (13) | 49 (17) | |
| 2 | 19 (19) | 17 (9) | 36 (13) | |
| 3 | 6 (6) | 2 (1) | 8 (3) | |
| 4 | 3 (3) | 0 (0) | 3 (1) | |
| Unknown | 36 (36) | 104 (57) | 140 (50) | |
| HIV status | HIV-negative | 59 (59) | 146 (81) | 205 (73) |
| HIV-positive | 24 (24) | 6 (3) | 30 (11) | |
| Unknown | 17 (17) | 29 (16) | 46 (16) | |
| First-line regimen | CODOX/IVAC±R | 34 (34) | 3 (2) | 37 (13) |
| COM | 0 (0) | 39 (22) | 39 (14) | |
| COP | 0 (0) | 16 (9) | 16 (6) | |
| DA-EPOCH±R | 6 (6) | 9 (5) | 15 (5) | |
| No treatment | 0 (0) | 5 (3) | 5 (2) | |
| Other | 8 (8) | 6 (3) | 14 (5) | |
| Unknown | 52 (52) | 103 (57) | 155 (55) | |
| PFS | Median, y | 2.87 | 0.85 | 1.64 |
| No. (%) | 88 (88) | 165 (91) | 253 (90) | |
| OS | Median, y | 2.89 | 1.02 | 1.82 |
| No. (%) | 88 (88) | 165 (91) | 253 (90) |
Data are given as number (percentage) of each group, unless otherwise indicated.
BLIPI, Burkitt Lymphoma International Prognostic Index; CODOX, cyclophosphamide, vincristine, doxorubicin; COM, cyclophosphamide, vincristine, methotrexate; COP, cyclophosphamide, vincristine, prednisone; DA-EPOCH, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin; IVAC, ifosfamide, etoposide, and cytarabine; OS, overall survival; PFS, progression-free survival; R, Rituximab.